|drug3545||Unfractionated Heparin IV Wiki||1.00|
|drug1194||Enoxaparin 1 mg/kg Wiki||1.00|
|drug1195||Enoxaparin 40 Mg/0.4 mL Injectable Solution Wiki||0.71|
|D054556||Venous Thromboembolism NIH||0.33|
There is one clinical trial.
This is a multicenter, open-label, 2x2 factorial, randomized-controlled trial in critically-ill patients with novel coronavirus disease 2019 (COVID-19) evaluating the efficacy and safety of full-dose vs. standard prophylactic dose anticoagulation and of antiplatelet vs. no antiplatelet therapy for prevention of venous and arterial thrombotic events.
Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemia, or clinically silent DVTMeasure: Primary endpoint: Venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlier
Description: Hierarchical composite: Death due to venous or arterial thrombosis, pulmonary embolism, clinically evident DVT, type 1 MI, ischemic stroke, systemic embolism or acute limb ischemiaMeasure: Key secondary endpoint: Clinically evident venous or arterial thrombotic events Time: 28 days or until hospital discharge, whichever earlier
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports